Overview

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Status:
Recruiting
Trial end date:
2025-07-08
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of AZD6912 administered subcutaneously (SC) in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca